Targeting rare and metabolic diseases with transformative therapies

Rezolute, Inc. is developing transformative therapies for rare and metabolic diseases. The company’s lead phase 2 candidate RZ358, has received orphan designation in both the US and Europe and is now on the path to potentially becoming a universal treatment for the disorder

Go to the profile of Rezolute Bio
Nov 21, 2019
0
0
Page of

No comments yet.